MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
6.15
+0.14 (2.42%)
Jun 9, 2025, 10:33 AM - Market open
MeiraGTx Holdings Employees
As of December 31, 2024, MeiraGTx Holdings had 381 total employees, including 375 full-time and 6 part-time employees. The number of employees decreased by 44 or -10.35% compared to the previous year.
Employees
381
Change (1Y)
-44
Growth (1Y)
-10.35%
Revenue / Employee
$90,572
Profits / Employee
-$439,186
Market Cap
493.85M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
MGTX News
- 26 days ago - MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting - GlobeNewsWire
- 27 days ago - MeiraGTx Reports First Quarter 2025 Financial and Operational Results - GlobeNewsWire
- 4 weeks ago - MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease - GlobeNewsWire
- 5 weeks ago - Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more - GlobeNewsWire
- 2 months ago - MeiraGTx Holdings: Gaining Regulatory Focus - Seeking Alpha
- 3 months ago - MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars - Benzinga
- 3 months ago - MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates - GlobeNewsWire
- 3 months ago - MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process - GlobeNewsWire